Close

Press Releases

Thermo Fisher Expands Clinical and Commercial Capabilities for Plasmid DNA Manufacturing

Thermo Fisher Scientific, the world leader in serving science, today announced the construction of a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif. The site will expand the company's clinical and commercial capabilities for cGMP plasmid DNA used...

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Aurinia Pharmaceuticals Inc. announced they have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement to build a dedicated manufacturing capacity within Lonza’s existing small molecule API facility in Visp, Switzerland. The dedicated facility (also referred...

Thermo Fisher Scientific Expands Clinical Supply Chain Services in Europe

To meet accelerating demand for robust clinical supply chain services throughout Europe, Thermo Fisher Scientific has expanded its pharma services footprint with two new state-of-the-art facilities in Rheinfelden and Weil am Rhein, Germany. The new sites will bring much-needed...

Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients

Roche announced that it has launched a high-throughput SARS-CoV-2 antigen test as an aid in the diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections, in markets accepting the CE Mark. Roche has also filed for Emergency Use...

UPS To Support Distribution Of Approved Vaccine As Part Of Operation Warp Speed

UPS announced its involvement and full support of distribution efforts for Pfizer-BioNTech’s COVID-19 vaccine as part of Operation Warp Speed. Pfizer’s and BioNTech’s vaccine, approved through a U.S. FDA EUA, is the first to be deployed in a months-long...

FedEx to Ship First Wave of COVID-19 Vaccines Across the United States

FedEx Express, a subsidiary of FedEx Corp. and the world’s largest express transportation company, announced that operations are in motion to transport its first shipments of COVID-19 vaccines. Following the Food and Drug Administration’s approval of Emergency Use Authorization for...

Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib as a Treatment for Patients with COVID-19 Associated Cytokine Storm

Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi®), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did not meet...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »